Scarica l'app Stockscreener
1.09
3.77%
0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance
H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
BioXcel Therapeutics, Inc. Share Price TodayLive NASDAQ: BTAI Stock Price Charts, History - Upstox
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia
Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com
BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Enrollment of First Patients - GlobeNewswire
BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus
FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks
BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - marketscreener.com
FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK
FDA accepts BioXcel filing for at-home agitation treatment - Investing.com
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan
BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI
BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI
BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget
Why are BioXcel Therapeutics shares down Friday? - MSN
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
1.68%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):